About Satellos Biosciences
pathways for medicines
Satellos is exploring new pathways for medicines to improve the treatment of degenerative muscle diseases.
Founded on breakthrough research in muscle stem cell biology, the company’s lead drug candidate is an oral, small molecule medicine in development as a potential disease-modifying treatment for Duchenne muscular dystrophy.
The company applies its proprietary discovery platform, called MyoReGenX™, to identify muscle diseases and disorders where muscle tissue is lost or muscle regeneration is defective. With this platform, Satellos then generates novel drug candidates designed to enhance muscle tissue growth and repair to restore muscle function.
Our world renowned team includes leading experts in muscle biology, who have authored landmark studies, as well as industry veterans and experienced drug developers, who have led multiple companies at the edge of science to advance novel therapeutics. Our team brings proven innovation, scientific discipline, and deep experience to advance meaningful therapeutics for patients with degenerative muscle diseases.